Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preemptive Treatment With Venetoclax Plus Azacitidine in Patients Diagnosed With Acute Myeloid Leukemia (AML) With Persistence or Reappearance of Measurable Residual Disease (MRD) After Frontline Chemotherapy and High-level MRD Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT)

NCT06668558 is registered in ClinicalTrials.gov with Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias as lead sponsor.

NCT NCT06668558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06668558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preemptive Treatment With Venetoclax Plus Azacitidine in Patients Diagnosed With Acute Myeloid Leukemia (AML) With Persistence or Reappearance of Measurable Residual Disease (MRD) After Frontline Chemotherapy and High-level MRD Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT)
Lead sponsor
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 16, 2024
Completion date
July 31, 2028
Enrollment
28 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia